Provided by Tiger Fintech (Singapore) Pte. Ltd.

Editas Medicine

1.54
+0.09006.21%
Post-market: 1.49-0.0501-3.25%17:05 EDT
Volume:3.33M
Turnover:5.30M
Market Cap:128.91M
PE:-0.53
High:1.77
Open:1.55
Low:1.47
Close:1.45
Loading ...

Editas Medicine Q1 EPS $(0.92) Misses $(0.59) Estimate, Sales $4.66M Beat $706.00K Estimate

Benzinga
·
33 mins ago

Editas Medicine Inc. to Showcase Preclinical Gene Editing Advances at ASGCT Annual Meeting

Reuters
·
34 mins ago

BRIEF-Editas Medicine Q1 Net Income USD -76.088 Million

Reuters
·
36 mins ago

Editas Medicine Inc - Cash Runway Into Q2 2027

THOMSON REUTERS
·
37 mins ago

Editas Medicine Announces First Quarter 2025 Results and Business Updates

THOMSON REUTERS
·
37 mins ago

Editas Medicine Q1 Operating Income USD -76.163 Million

THOMSON REUTERS
·
37 mins ago

Editas Medicine : Co's in-Licensed Patents Covering CRISPR/Cas12a Are Not at Issue in Interference and Are Unaffected by This Decision

THOMSON REUTERS
·
1 hour ago

Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board

THOMSON REUTERS
·
1 hour ago

North American Morning Briefing: Stock Futures Surge on China Deal

Dow Jones
·
Yesterday

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Yesterday

H.C. Wainwright Remains a Buy on Editas Medicine (EDIT)

TIPRANKS
·
06 May

Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May

GlobeNewswire
·
06 May

Editas Medicine Inc expected to post a loss of 58 cents a share - Earnings Preview

Reuters
·
02 May

Editas Medicine (EDIT) Gets a Sell from Bank of America Securities

TIPRANKS
·
30 Apr

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
30 Apr

Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

GlobeNewswire
·
29 Apr

Editas Medicine Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
28 Apr

HC Wainwright Initiates Coverage on Editas Medicine With Buy Rating, $3 Price Target

MT Newswires Live
·
28 Apr